Literature DB >> 9138277

Are alanine aminotransferase, hepatitis B virus DNA or IgM antibody to hepatitis B core antigen serum levels predictors of histological grading in chronic hepatitis B?

C Zavaglia1, L Mondazzi, G Maggi, G Iamoni, F Gelosa, G Bellati, G Colloredo, R Bottelli, G Ideo.   

Abstract

Paired sera and liver biopsies from 105 patients with chronic hepatitis B virus infection (34 HBeAg positive and 71 anti-HBe positive) were studied to investigate the relation between the degree of histological activity and alanine aminotransferase (ALT), hepatitis B virus DNA (HBV-DNA) or IgM antibody to hepatitis B core antigen (IgM anti-HBc) levels. ALT levels were significantly higher in patients with piecemeal necrosis (155 +/- 124 vs 75 +/- 42, p = 0.0017), but there were no differences in the ALT values of patients with or without intralobular necrosis. ALT values were within normal range in 29% of 31 patients without versus 15% of 65 with piecemeal necrosis (p = 0.19). Serum HBV-DNA levels were not related to the grade of lobular or portal/periportal activity in HBeAg-positive patients. Anti-HBe-positive subjects with piecemeal necrosis had higher HBV-DNA levels (34 +/- 93 vs 4 +/- 6, p = 0.01). IgM anti-HBc indexes were significantly higher in patients with intralobular necrosis (0.635 +/- 0.600 vs 0.356 +/- 0.367, p = 0.0005) or piecemeal necrosis (0.671 +/- 0.633 vs 0.321 +/- 0.219, p = 0.0002). In summary, since serum IgM anti-HBc-IMx indexes can reflect the grade of histological activity, the quantitative assessment of this antibody could be useful for non-invasive monitoring of hepatocellular damage in chronic hepatitis B.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9138277     DOI: 10.1111/j.1600-0676.1997.tb00785.x

Source DB:  PubMed          Journal:  Liver        ISSN: 0106-9543


  6 in total

1.  Performance characteristics of microparticle enzyme and chemiluminescence immunoassays for measurement of anti-HBc immunoglobulin M in sera of patients with HBeAg-negative chronic hepatitis B virus infection.

Authors:  Emilia Hadziyannis; Emanuel Manesis; Dimitrios Vassilopoulos; Anastasia Georgiou; Athanasios Archimandritis
Journal:  Clin Vaccine Immunol       Date:  2007-12-12

2.  Hepatitis B e-antigen persistency is associated with the properties of HBV-specific CD8 T cells in CHB patients.

Authors:  Guoping Peng; Benyan Luo; Jie Li; Dongjiu Zhao; Wei Wu; Feng Chen; Zhi Chen
Journal:  J Clin Immunol       Date:  2010-12-01       Impact factor: 8.317

3.  Evaluation of the need for treatment on 72 subjects with anti-HBe positive chronic hepatitis B.

Authors:  Shima Soleimani Amiri; Shariar Shafaee; Mohammad Reza Hasanjani Roushan; Masomeh Baiani; Mahmoud Hajiahmadi
Journal:  Caspian J Intern Med       Date:  2012

4.  A randomized, controlled study of thymosin-alpha1 therapy in patients with anti-HBe, HBV-DNA-positive chronic hepatitis B.

Authors:  C Zavaglia; R Severini; C Tinelli; J S Franzone; A Airoldi; S Tempini; G Bettale; G Ideo
Journal:  Dig Dis Sci       Date:  2000-04       Impact factor: 3.199

5.  Comparison of hepatitis B surface antigen and e antigen in predicting liver histology in hepatitis B e antigen-positive chronic hepatitis B patients.

Authors:  Hong Wang; Rong Yan; Yin Zhou; Ming Shan Wang; Guo Qin Ruo; Mei Juan Cheng
Journal:  Hepatol Int       Date:  2014-01-23       Impact factor: 6.047

6.  Characteristics of treatment naïve chronic hepatitis B in Bangladesh: younger populations are more affected; HBeAg-negatives are more advanced.

Authors:  Shanhinul Alam; Nooruddin Ahmad; Golam Mustafa; Khorshed Alam; Mobin Khan
Journal:  Saudi J Gastroenterol       Date:  2008-01       Impact factor: 2.485

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.